167 related articles for article (PubMed ID: 17417795)
1. Proliferative index and CD15 expression in pediatric classical Hodgkin lymphoma.
Dinand V; Malik A; Unni R; Arya LS; Pandey RM; Dawar R
Pediatr Blood Cancer; 2008 Feb; 50(2):280-3. PubMed ID: 17417795
[TBL] [Abstract][Full Text] [Related]
2. [Feasibility study of application of international prognostic score on prediction of prognosis for advanced Hodgkin's lymphoma].
Fu XH; Wang SS; Huang Y; Wang B; Huang HQ; Zhang L; Sun XF; Xu RH; Lin TY
Ai Zheng; 2006 Aug; 25(8):1013-8. PubMed ID: 16965685
[TBL] [Abstract][Full Text] [Related]
3. Survival improvement of young patients, aged 16-23, with Hodgkin lymphoma (HL) during the last three decades.
Koumarianou AA; Xiros N; Papageorgiou E; Pectasides D; Economopoulos T
Anticancer Res; 2007; 27(2):1191-7. PubMed ID: 17465262
[TBL] [Abstract][Full Text] [Related]
4. Comparison of treatment outcomes of childhood Hodgkin lymphoma in two US centers and a center in Recife, Brazil.
Hsu SC; Metzger ML; Hudson MM; Pedrosa F; Lins M; Pedrosa M; Barros C; Maciel K; Pui CH; Ribeiro RC; Howard SC
Pediatr Blood Cancer; 2007 Aug; 49(2):139-44. PubMed ID: 16642484
[TBL] [Abstract][Full Text] [Related]
5. Very high levels of soluble CD30 recognize the patients with classical Hodgkin's lymphoma retaining a very poor prognosis.
Visco C; Nadali G; Vassilakopoulos TP; Bonfante V; Viviani S; Gianni AM; Federico M; Luminari S; Peethambaram P; Witzig TE; Pangalis G; Cabanillas F; Medeiros LJ; Sarris AH; Pizzolo G
Eur J Haematol; 2006 Nov; 77(5):387-94. PubMed ID: 16879607
[TBL] [Abstract][Full Text] [Related]
6. [Over 30-year experience of Polish Pediatric Leukemia/Lymphoma Study Group for treatment of Hodgkin's disease in children and adolescents: improvement curability and decrease of serious complications].
Balwierz W; Moryl-Bujakowska A; Depowska T; Klekawka T; Stanuch H; Matysiak M; Sopyło B; Kołakowska-Mrozowska B; Krenke K; Chybicka A; Raś M; Sońta-Jakimczyk D; Moszant A; Wachowiak J; Kaczmarek-Kanold M; Kowalczyk J; Odój T; Balcerska A; Drozyńska E; Wysocki M; Kołtan A; Krawczuk-Rybak M; Stolarska M
Przegl Lek; 2004; 61 Suppl 2():33-9. PubMed ID: 15688474
[TBL] [Abstract][Full Text] [Related]
7. Escalated-dose BEACOPP in the treatment of patients with advanced-stage Hodgkin's lymphoma: 10 years of follow-up of the GHSG HD9 study.
Engert A; Diehl V; Franklin J; Lohri A; Dörken B; Ludwig WD; Koch P; Hänel M; Pfreundschuh M; Wilhelm M; Trümper L; Aulitzky WE; Bentz M; Rummel M; Sezer O; Müller-Hermelink HK; Hasenclever D; Löffler M
J Clin Oncol; 2009 Sep; 27(27):4548-54. PubMed ID: 19704068
[TBL] [Abstract][Full Text] [Related]
8. Comparison between hybrid MOPPABV and ABVD chemotherapy protocols for Hodgkin's lymphoma in public hospitals of the largest South American city: a retrospective 14-year study.
Souza EM; Baiocchi OC; Zanichelli MA; Alves AC; Oliveira JS
Ann Hematol; 2009 Jul; 88(7):633-7. PubMed ID: 18998131
[TBL] [Abstract][Full Text] [Related]
9. Hodgkin's lymphoma in adolescents.
Foltz LM; Song KW; Connors JM
J Clin Oncol; 2006 Jun; 24(16):2520-6. PubMed ID: 16735704
[TBL] [Abstract][Full Text] [Related]
10. Expression of bcl-2 in classical Hodgkin's lymphoma: an independent predictor of poor outcome.
Sup SJ; Alemañy CA; Pohlman B; Elson P; Malhi S; Thakkar S; Steinle R; Hsi ED
J Clin Oncol; 2005 Jun; 23(16):3773-9. PubMed ID: 15809450
[TBL] [Abstract][Full Text] [Related]
11. Classical Hodgkin's disease. Clinical impact of the immunophenotype.
von Wasielewski R; Mengel M; Fischer R; Hansmann ML; Hübner K; Franklin J; Tesch H; Paulus U; Werner M; Diehl V; Georgii A
Am J Pathol; 1997 Oct; 151(4):1123-30. PubMed ID: 9327746
[TBL] [Abstract][Full Text] [Related]
12. [Treatment results of stage IA Hodgkin lymphoma: a report of 97 cases].
Tan WY; Hu DS; Zeng FY; Song QB; Hu S; Wei L; Zhou LQ
Ai Zheng; 2007 Dec; 26(12):1360-4. PubMed ID: 18076802
[TBL] [Abstract][Full Text] [Related]
13. Survival and late effects in children with Hodgkin's lymphoma treated with MOPP/ABV and low-dose, extended-field irradiation.
Chow LM; Nathan PC; Hodgson DC; Jenkin D; Weitzman S; Grant RM; Manson D; Bross A; Doyle JJ; Danjoux C; Greenberg ML
J Clin Oncol; 2006 Dec; 24(36):5735-41. PubMed ID: 17179107
[TBL] [Abstract][Full Text] [Related]
14. Prognostic impact of CD15 expression and proliferative index in the outcome of children with classical Hodgkin lymphoma.
Barros MH; Zalcberg IR; Hassan R
Pediatr Blood Cancer; 2008 Feb; 50(2):428-9; author reply 430. PubMed ID: 17973313
[No Abstract] [Full Text] [Related]
15. HLA class II expression by Hodgkin Reed-Sternberg cells is an independent prognostic factor in classical Hodgkin's lymphoma.
Diepstra A; van Imhoff GW; Karim-Kos HE; van den Berg A; te Meerman GJ; Niens M; Nolte IM; Bastiaannet E; Schaapveld M; Vellenga E; Poppema S
J Clin Oncol; 2007 Jul; 25(21):3101-8. PubMed ID: 17536082
[TBL] [Abstract][Full Text] [Related]
16. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
[TBL] [Abstract][Full Text] [Related]
17. Results of treatment of 112 cases of primary CNS lymphoma.
Yamanaka R; Morii K; Shinbo Y; Homma J; Sano M; Tsuchiya N; Yajima N; Tamura T; Hondoh H; Takahashi H; Kakuma T; Tanaka R
Jpn J Clin Oncol; 2008 May; 38(5):373-80. PubMed ID: 18413337
[TBL] [Abstract][Full Text] [Related]
18. Low apoptotic index & bak expression in EBV-associated childhood classical Hodgkin lymphoma.
Dinand V; Malik A; Mohanty B; Chander B; Arya LS; Dawar R
Indian J Med Res; 2009 Nov; 130(5):526-32. PubMed ID: 20090100
[TBL] [Abstract][Full Text] [Related]
19. Contemporary treatment options for a classical disease: Advanced Hodgkin lymphoma.
Reid JH; Marini BL; Nachar VR; Brown AM; Devata S; Perissinotti AJ
Crit Rev Oncol Hematol; 2020 Apr; 148():102897. PubMed ID: 32109715
[TBL] [Abstract][Full Text] [Related]
20. Comparison of MOPP/MOPP +/- RT vs. MOPp/ABVD +/- RT in poor prognosis Hodgkin's disease. Long-term results.
Comella P; Abate G; Fiore M; Di Finizio G; Frezza P; Scoppa G; Anania C; Coucourde F; Zarrilli D
J Chemother; 1989 Jul; 1(4 Suppl):1254-6. PubMed ID: 16312855
[No Abstract] [Full Text] [Related]
[Next] [New Search]
